Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 13/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 12/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 12/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | CFB | P00751 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13616137 | 0.85 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CADRA1ACYP3A4 | |
| SCHEMBL16509904 | 0.84 | ADRA2A (0.39) | ADRA2AADRA2BADRA2CADRA1ACYP3A4 | |
| SCHEMBL13616138 | 0.84 | CFB (0.36) | ADRA2AADRA2BADRA2CADRA1ACYP3A4 | |
| SCHEMBL13616139 | 0.80 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CADRA1ACYP3A4 | |
| SCHEMBL1120243 | 0.78 | ADRA2A (0.39) | ADRA2AADRA2BADRA2CADRA1ACYP3A4 | |
| SCHEMBL11250505 | 0.77 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1ACYP3A4 | |
| SCHEMBL9883869 | 0.76 | TAAR1 (0.50) | ADRA2AADRA2BADRA2CADRA1ACYP3A4 | |
| SCHEMBL2017610 | 0.76 | TAAR1 (0.50) | ADRA2AADRA2BADRA2CADRA1ACYP3A4 | |
| SCHEMBL1784726 | 0.76 | TAAR1 (0.50) | ADRA2AADRA2BADRA2CADRA1ACYP3A4 | |
| SCHEMBL11248212 | 0.76 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CADRA1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080570-B2 | α2B and α2C agonists | ALLERGAN, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080570-B2 | α2B and α2C agonists | ALLERGAN, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080570-B2 | α2B and α2C agonists | ALLERGAN, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2280707-A1 | ALPHA2B AND ALPHA2C AGONISTS | Allergan, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009137340-A1 | ALPHA2B AND ALPHA2C AGONISTS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137340-A1 | ALPHA2B AND ALPHA2C AGONISTS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090275627-A1 | ALPHA2B AND ALPHA2C AGONISTS | ALLERGAN, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275627-A1 | ALPHA2B AND ALPHA2C AGONISTS | ALLERGAN, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275627-A1 | ALPHA2B AND ALPHA2C AGONISTS | ALLERGAN, INC. (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275627-A1 | ALPHA2B AND ALPHA2C AGONISTS | ADRA2B, ADRA2C, ADRB2 | ADRA2A 4/4885ADRA2B 1/4885ADRA2C 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.